PUT - SPRINTER OPEN END - BIOGEN IDEC | Delayed Deutsche Boerse AG 15:54:56 22/05/2024 BST | ||
| 8.39 EUR | +2.57% |
|
| Current month | -11.09% | ||
| 1 month | -28.37% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
Latest news about BIOGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 22/05/24 | 8.39 | +2.57% |
| 21/05/24 | 8.18 | +6.65% |
| 20/05/24 | 7.67 | -2.79% |
| 17/05/24 | 7.89 | -0.13% |
| 16/05/24 | 7.9 | +8.82% |
Delayed Quote Deutsche Boerse AG
Last update May 22, 2024 at 03:54 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | BIOGEN INC. |
| Issuer | 
Vontobel
|
| WKN | VU8LNN |
| ISIN | DE000VU8LNN4 |
| Date issued | 14/06/2023 |
| Strike | 312.5 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.23 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 11.63 € |
|---|---|
| Lowest since issue | 0.89 € |
| Spread | 0.03 € |
| Spread % | 0.36% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
227.7
USD
Average target price
285.9
USD
Spread / Average Target
+25.57%
- Stock Market
- Certificates
- Certificat
